Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel
NYSEAMERICAN:OGEN

Oragenics 3/16/2026 Earnings Report

Oragenics logo
$0.60 -0.02 (-2.61%)
Closing price 05/8/2026 04:10 PM Eastern
Extended Trading
$0.62 +0.02 (+3.85%)
As of 05/8/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings History

Oragenics EPS Results

Actual EPS
$0.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oragenics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oragenics Announcement Details

Quarter
Date
3/16/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Oragenics Earnings Headlines

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
May 7 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290005/0/en/oragenics-signs-letter-of-intent-to-license-cardiodialysis-technology-from-sigyn-therapeutics-to-target-tbi-induced-systemic-inflammation.html
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
May 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287664/0/en/oragenics-activates-second-site-in-phase-iia-clinical-trial-of-onp-002-for-concussion-and-mild-traumatic-brain-injury.html
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
May 9 at 1:00 AM  |  Brownstone Research (Ad)
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
April 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/oragenics-reports-8-study-drug-130000010.html
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
April 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/13/3272489/0/en/oragenics-doses-first-patient-in-phase-iia-clinical-trial-of-onp-002-for-mild-traumatic-brain-injury.html
Oragenics, Inc. Receives Unqualified Audit Opinion with Going Concern Explanatory Paragraph in Latest Annual Report
March 25, 2026  |  quiverquant.comQ
See More Oragenics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oragenics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oragenics and other key companies, straight to your email.

About Oragenics

Oragenics (NYSEAMERICAN:OGEN) is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures. In addition to its dental portfolio, Oragenics is advancing Ogi-04™, a therapeutic candidate for the prevention and treatment of oral mucositis, a common and painful side effect of cancer therapy. Oragenics’ research pipeline also includes earlier-stage programs aimed at broad-spectrum anti-infective applications.

Founded in 1996, Oragenics has built a foundation of proprietary peptide and gene-based platforms that support its drug discovery and development efforts. The company operates primarily in the United States but seeks to establish strategic collaborations to extend its reach into additional markets. Oragenics is listed on the New York Stock Exchange under the ticker symbol OGEN.

Oragenics is led by President and Chief Executive Officer Todd Korth, whose leadership and financial expertise have guided the company’s strategic direction and operational execution. The management team combines scientific experience with regulatory and commercial know-how to advance the company’s clinical programs toward potential commercialization.

View Oragenics Profile
Earnings Tools